Also known as: GLP-1 agonist, GLP-1 pill, GLP-1R agonists, GLP-1 weight loss drug, GLP-1 weight-loss drug, GLP-1 weight-loss drugs
A retrospective cohort study of 14,118 matched pairs found tirzepatide associated with lower risks of stroke and death than other GLP-1 receptor agonists in patients with atrial fibrillation and type 2 diabetes. Absolute differences were 2.1 percentage points for stroke and 6.2 for mortality at one year. Randomized trials are needed before recommendations change.
New research shows GLP-1 receptor agonists are associated with reduced asthma exacerbation risk in overweight, obese, and morbidly obese patients without diabetes, with risk reductions of 14.6%, 12.2%, and 13.3% respectively. The findings were presented at the 2026 AAAAI Annual Meeting.
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
TMates Weightloss Semaglutide is a compounded semaglutide telehealth program dispensed by U.S. pharmacies. It offers tailored dosing, a 30-day money-back guarantee, and support for appetite control and weight maintenance.
Physician-supervised clinics in Florida and Texas offer semaglutide and tirzepatide weight loss programs. Clinical trials show average weight loss of 15% with semaglutide and about 21% with tirzepatide. All-inclusive monthly plans start at $349.
One in eight U.S. adults now takes a GLP-1, and prescriptions among non-diabetics rose 700% since 2019. The market is projected to reach $200 billion by 2030, driving manufacturing investments and consumer food shifts.
The UK MHRA approved oral semaglutide (Wegovy) as the first GLP-1 weight loss tablet on 11 June 2026. A new report links high-dose tirzepatide to anhedonia, and data show bariatric surgery declining sharply as GLP-1 use surges.
Semaglutide improves kidney, survival, and quality-of-life outcomes in type 2 diabetes with CKD, per FLOW trial analyses. Benefits were consistent across cardiovascular and severity subgroups, adding eight full-health days per year.
New studies link GLP-1 drugs to eating disorders, erectile dysfunction and relationship changes, while Deloitte reports the drugs' market boom has lifted pharma R&D returns but created a concentration risk.
HHS launches broad initiative to boost US clinical trials amid global competition with China. FDA introduces real-time clinical trial monitoring and expedited programs. NIH Long COVID trials set to begin enrolling participants in summer 2026.
